CL2014000428A1 - Metodo para el tratamiento de hepatitis c (hcv) que comprende administrar un compuesto de formula (i), (ii) o (iii) en combinacion con uno o mas agentes terapeuticos; composicion farmaceutica. - Google Patents

Metodo para el tratamiento de hepatitis c (hcv) que comprende administrar un compuesto de formula (i), (ii) o (iii) en combinacion con uno o mas agentes terapeuticos; composicion farmaceutica.

Info

Publication number
CL2014000428A1
CL2014000428A1 CL2014000428A CL2014000428A CL2014000428A1 CL 2014000428 A1 CL2014000428 A1 CL 2014000428A1 CL 2014000428 A CL2014000428 A CL 2014000428A CL 2014000428 A CL2014000428 A CL 2014000428A CL 2014000428 A1 CL2014000428 A1 CL 2014000428A1
Authority
CL
Chile
Prior art keywords
hcv
hepatitis
administering
iii
compound
Prior art date
Application number
CL2014000428A
Other languages
English (en)
Spanish (es)
Inventor
Jill Walker
Christian Voitenleitner
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of CL2014000428A1 publication Critical patent/CL2014000428A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CL2014000428A 2011-08-24 2014-02-21 Metodo para el tratamiento de hepatitis c (hcv) que comprende administrar un compuesto de formula (i), (ii) o (iii) en combinacion con uno o mas agentes terapeuticos; composicion farmaceutica. CL2014000428A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161526798P 2011-08-24 2011-08-24
US201161529358P 2011-08-31 2011-08-31
US201261617813P 2012-03-30 2012-03-30

Publications (1)

Publication Number Publication Date
CL2014000428A1 true CL2014000428A1 (es) 2014-08-01

Family

ID=47746891

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014000428A CL2014000428A1 (es) 2011-08-24 2014-02-21 Metodo para el tratamiento de hepatitis c (hcv) que comprende administrar un compuesto de formula (i), (ii) o (iii) en combinacion con uno o mas agentes terapeuticos; composicion farmaceutica.

Country Status (18)

Country Link
US (1) US20140234253A1 (enExample)
EP (1) EP2747569A4 (enExample)
JP (2) JP2014527061A (enExample)
KR (1) KR20140065427A (enExample)
CN (1) CN103917095A (enExample)
AU (1) AU2012298750A1 (enExample)
BR (1) BR112014004182A2 (enExample)
CA (1) CA2845321A1 (enExample)
CL (1) CL2014000428A1 (enExample)
CO (1) CO6890100A2 (enExample)
CR (1) CR20140086A (enExample)
EA (1) EA201490254A1 (enExample)
HK (1) HK1198869A1 (enExample)
IL (1) IL230844A0 (enExample)
MX (1) MX2014002171A (enExample)
PH (1) PH12014500386A1 (enExample)
SG (1) SG2014010490A (enExample)
WO (1) WO2013028953A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102480971B (zh) * 2009-09-04 2014-11-26 杨森制药公司 化合物
ES2735542T3 (es) 2011-08-17 2019-12-19 Glaxosmithkline Llc Procedimientos terapéuticos
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
ES2529143B1 (es) 2011-10-21 2015-10-26 Abbvie Inc. Combinación de al menos dos agentes antivirales de acción directa, ribavirina pero no interferón para uso de tratamiento del vhc
CH707030B1 (de) 2011-10-21 2015-03-13 Abbvie Inc Kombinationsbehandlung von DAAs zur Verwendung in der Behandlung von HCV
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
RU2015148006A (ru) 2013-04-12 2017-05-18 Ачиллион Фармасютикалз, Инк. Дейтерированные нуклеозидные пролекарства, применимые для лечения hcv
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
CN105517574B (zh) * 2013-07-09 2019-01-18 百时美施贵宝公司 丙型肝炎病毒抑制剂的组合产品
JP2016527232A (ja) 2013-07-17 2016-09-08 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｈｃｖの治療に使用するためのビフェニル誘導体を含む組み合わせ
CN104725365B (zh) * 2013-12-23 2019-02-26 南京圣和药业股份有限公司 丙型肝炎病毒抑制剂及其应用
CN105873922B (zh) * 2013-12-31 2018-08-14 南京圣和药业股份有限公司 9,9,10,10-四氟-9,10二氢菲类丙型肝炎病毒抑制剂及其应用
CN105073740B (zh) * 2014-01-21 2017-06-27 杭州普晒医药科技有限公司 一种化合物的盐及晶型或无定型物、其制备方法、含有它们的药物组合物和用途
CA2967195A1 (en) * 2014-11-10 2016-05-19 Glaxosmithkline Intellectual Property (No.2) Limited Long acting pharmaceutical compositions for hepatitis c
MA41812A (fr) * 2015-03-27 2018-01-30 Janssen Pharmaceuticals Inc Procédés et intermédiaires pour la préparation d'un inhibiteur de protéase macrocyclique du vhc
US10617675B2 (en) 2015-08-06 2020-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP3448392A4 (en) 2016-04-28 2020-01-15 Emory University ALKYNOUS THERAPEUTIC NUCLEOTIDE AND NUCLEOSIDE COMPOSITIONS AND RELATED APPLICATIONS
CN110693887B (zh) * 2019-05-17 2022-06-17 歌礼药业（浙江）有限公司 包含索磷布韦和拉维达韦的片剂及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8303944B2 (en) * 2006-08-11 2012-11-06 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20100158862A1 (en) * 2006-08-11 2010-06-24 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US8329159B2 (en) * 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7704992B2 (en) * 2008-02-13 2010-04-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TWI480272B (zh) * 2008-10-09 2015-04-11 Anadys Pharmaceuticals Inc 藉由５，６－二氫－１ｈ－吡啶－２－酮與一或多種其他抗病毒化合物的組合物抑制ｃ型肝炎病毒的方法
US8729077B2 (en) * 2008-11-28 2014-05-20 Glaxosmithkline Llc Anti-viral compounds, compositions, and methods of use
CA2750227A1 (en) * 2009-01-07 2010-07-15 Scynexis, Inc. Cyclosporine derivative for use in the treatment of hcv and hiv infection
BRPI1010795B1 (pt) * 2009-05-13 2018-12-11 Gilead Pharmasset Llc compostos antivirais, seu uso e composição farmacêutica compreendendo os mesmos
CN102480971B (zh) * 2009-09-04 2014-11-26 杨森制药公司 化合物
US8415374B2 (en) * 2009-10-12 2013-04-09 Bristol-Myers Squibb Company Combinations of hepatitis C virus inhibitors
US8377980B2 (en) * 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
RU2554087C2 (ru) * 2009-12-18 2015-06-27 Айденикс Фармасьютикалз, Инк. 5,5-конденсированные ариленовые или гетероариленовые ингибиторы вируса гепатита с
WO2012040126A1 (en) * 2010-09-22 2012-03-29 Alios Biopharma, Inc. Substituted nucleotide analogs

Also Published As

Publication number Publication date
JP2014527061A (ja) 2014-10-09
MX2014002171A (es) 2014-04-25
WO2013028953A1 (en) 2013-02-28
US20140234253A1 (en) 2014-08-21
JP2017165746A (ja) 2017-09-21
EP2747569A1 (en) 2014-07-02
SG2014010490A (en) 2014-04-28
CO6890100A2 (es) 2014-03-10
KR20140065427A (ko) 2014-05-29
PH12014500386A1 (en) 2019-10-07
CR20140086A (es) 2014-05-02
EA201490254A1 (ru) 2014-07-30
BR112014004182A2 (pt) 2017-03-14
CN103917095A (zh) 2014-07-09
EP2747569A4 (en) 2015-07-08
HK1198869A1 (en) 2015-06-19
IL230844A0 (en) 2014-03-31
CA2845321A1 (en) 2013-02-28
AU2012298750A1 (en) 2014-03-13

Similar Documents

Publication Publication Date Title
CL2014000428A1 (es) Metodo para el tratamiento de hepatitis c (hcv) que comprende administrar un compuesto de formula (i), (ii) o (iii) en combinacion con uno o mas agentes terapeuticos; composicion farmaceutica.
CL2013001428A1 (es) Compuesto que inhibe la actividad del virus de la hepatitis c (hcv); composición farmacéutica que comprende el compuesto; método de tratamiento de hepatitis c.
UY33183A (es) Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento
CL2014002093A1 (es) Compuestos derivados piperidinopirimidinicos; composicion farmaceutica que los comprende; uso en el tratamiento de infecciones viricas.
ECSP12012103A (es) Inhibidores de virus flaviviridae.
PE20141906A1 (es) Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento
BR112015002541A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para tratamento de hcv em um paciente.
CL2015000295A1 (es) Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades.
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
MD4589B1 (ro) Compoziţie farmaceutică cu conţinut de sofosbuvir şi utilizarea acesteia în tratamentul hepatitei virale C
BR112014030649A2 (pt) inibidores macrocíclicos da flaviviridae vírus
CL2013002939A1 (es) Compuestos derivados de nucleosidos 2´-sustituidos , inhibidores ns5a; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c.
CL2008001005A1 (es) Compuestos derivados de azufre, inhibidores de la serina proteasa ns3 del virus de la hepatitis c; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos asociados a la proteasa de hcv.
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
IN2012DN01855A (enExample)
CL2014001047A1 (es) Compuestos heterociclicos derivados de pirazina; composicion y combinacion farmaceutica que los contienen y el uso en enfermedades respiratorias y alergicas.
CO7350640A2 (es) Compuestos diméricos
BR112014009950A2 (pt) composto dissubstituído, compostos e composição farmacêutica
BR112014013972A8 (pt) inibidores de hcv nssa
CO7131387A2 (es) Composiciones y métodos de polipéptidos-complejo de quelato de oligonucleótido
CL2014000394A1 (es) Uso de compuestos fenil-benzofuran-sulfamido sustituidos para el tratamiento del virus de la hepatitis c (hcv); y composicion farmaceutica que comprende a estos compuestos fenil-benzofuran-sulfamido sustituidos.
CO6920289A2 (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib.
CL2013001910A1 (es) Compuestos derivados de fenil-isoxazol; metodo para prepararlos; composicion farmaceutica que los comprende; combinacion que los comprende junto a otro agente terapeutico o preventivo de infecciones virales; metodo para prevenir o tratar infecciones virales; y su uso para el tratamiento de infecciones virales.
ECSP13012369A (es) Agentes terapéuticos 976
CL2014001663A1 (es) Metodo para tratar una enfermedad desmielinizante tal como esclerosis multiple que comprende administrar compuestos andrografolidos y una interferona; y su uso para tratar una enfermedad desmielinizante tal como esclerosis multiple.